Please wait...
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Paclitaxel protein-bound is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Paclitaxel protein-bound is used to treat cancer of the breast, lung, or pancreas.
Paclitaxel protein-bound is sometimes given with other cancer medicines.
Paclitaxel protein-bound may also be used for purposes not listed in this medication guide.
You should not be treated with paclitaxel protein-bound if you have a very low white blood cell count.
You should not be treated with this medicine if you are allergic to paclitaxel, or if you have:
a low white blood cell count;
severe liver disease.
Tell your doctor if you have ever had:
liver disease;
kidney disease; or
an allergic reaction to medicines like paclitaxel protein-bound (such as cabazitaxel or docetaxel).
Paclitaxel protein-bound can harm an unborn baby or cause birth defects if the mother or the father is using this medicine.
If you are a woman, do not use paclitaxel protein-bound if you are pregnant. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 6 months after your last dose.
If you are a man, use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 3 months after your last dose.
Tell your doctor right away if a pregnancy occurs while either the mother or the father is using paclitaxel protein-bound.
This medicine may affect fertility (ability to have children) in both men and women. However, it is important to use birth control to prevent pregnancy because paclitaxel protein-bound can harm an unborn baby.
Do not breast-feed while you are receiving this medicine, and for at least 2 weeks after your last dose.
Paclitaxel protein-bound is given as an infusion into a vein. A healthcare provider will give you this injection.
For breast cancer, paclitaxel protein-bound is usually given once every 3 weeks.
For cancer of the lung or pancreas, this medicine is given in a 21-day or 28-day treatment cycle. You will receive this medicine only on certain days of each cycle.
Your doctor will determine how long to treat you with this medicine.
Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when paclitaxel protein-bound is injected.
Paclitaxel protein-bound can lower your blood cell counts. Your blood will need to be tested often. Your cancer treatments may be delayed based on the results.
Call your doctor for instructions if you miss an appointment for your paclitaxel protein-bound injection.
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Paclitaxel protein-bound can be harmful if it gets in your eyes, mouth, or nose, or on your skin. If skin contact occurs, wash the area with soap and water or rinse the eyes thoroughly with plain water.
paclitaxel protein-bound can pass into body fluids (urine, feces, vomit). For at least 48 hours after you receive a dose, avoid allowing your body fluids to come into contact with your hands or other surfaces. Caregivers should wear rubber gloves while cleaning up a patient's body fluids, handling contaminated trash or laundry or changing diapers. Wash hands before and after removing gloves. Wash soiled clothing and linens separately from other laundry.
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Call your doctor at once if you have:
numbness, tingling, pain, or weakness in your hands or feet;
sudden chest pain or discomfort, rapid heart rate;
dry cough, shortness of breath, rapid and shallow breathing;
dehydration symptoms--headache, muscle pain, feeling very thirsty or hot, being unable to urinate, dark urine, dry mouth, hot and dry skin; or
low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath.
Common side effects may include:
fever, chills, or other signs of infection;
numbness or tingling;
hair loss, rash;
nausea, vomiting, diarrhea, loss of appetite;
irregular heartbeats, shortness of breath;
feeling weak or tired;
muscle and joint pain;
swelling in your hands or feet;
abnormal liver function tests; or
dehydration.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Breast Cancer:
260 mg/m2 IV over 30 minutes every 3 weeks
Use: For metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy; prior therapy should have included an anthracycline unless clinically contraindicated
Usual Adult Dose for Non-Small Cell Lung Cancer:
100 mg/m2 IV over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after paclitaxel protein-bound
Use: For locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
Usual Adult Dose for Pancreatic Cancer:
125 mg/m2 IV over 30 to 40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine immediately after paclitaxel protein-bound on Days 1, 8 and 15 of each 28-day cycle
Use: For metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine
Other drugs may affect paclitaxel protein-bound, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Paclitaxel (www.drugs.com/mtm/paclitaxel-protein-bound.html).
Commonly reported side effects of paclitaxel protein-bound include: infection, severe peripheral sensory neuropathy, bone marrow depression, neutropenia, alopecia, anemia, and peripheral sensory neuropathy. Other side effects include: hypersensitivity reaction. See below for a comprehensive list of adverse effects.
Applies to paclitaxel protein-bound: intravenous powder for suspension
Intravenous route (Powder for Suspension)
Do not administer paclitaxel protein-bound particles for injectable suspension therapy to patients with baseline neutrophil counts less than 1500 cells/mm(3). Perform frequent peripheral blood counts to monitor the occurrence of bone marrow suppression. Do not substitute with other paclitaxel formulations.
Along with its needed effects, paclitaxel protein-bound may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking paclitaxel protein-bound:
More common
Less common
Some side effects of paclitaxel protein-bound may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Less common
Rare
Applies to paclitaxel protein-bound: intravenous powder for injection
Very common (10% or more): Alopecia (90%), rash
Common (1% to 10%): Nail disorder, pruritus, dry skin, erythema, nail pigmentation/discoloration, skin hyperpigmentation, onycholysis, nail changes
Uncommon (0.1% to 1%): Nail bed tenderness, urticaria, skin pain, photosensitivity reaction, pigmentation disorder, pruritic rash, skin disorder, hyperhidrosis, onychomadesis, erythematous rash, generalized rash, dermatitis, night sweats, maculopapular rash, vitiligo, hypotrichosis, nail discomfort, generalized pruritus, macular rash, papular rash, skin lesion, swollen face
Very rare (less than 0.01%): Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)
Very common (10% or more): Neutropenia (up to 82%), anemia (up to 25%), leukopenia, thrombocytopenia, lymphopenia, bone marrow suppression
Common (1% to 10%): Febrile neutropenia
Rare (less than 0.1%): Pancytopenia
Very common (10% or more): Peripheral neuropathy, neuropathy, hypoesthesia, paresthesia
Common (1% to 10%): Peripheral sensory neuropathy, headache, dysgeusia, dizziness, peripheral motor neuropathy, ataxia, sensory disturbance, somnolence
Uncommon (0.1% to 1%): Polyneuropathy, areflexia, dyskinesia, hyporeflexia, neuralgia, sensory loss, syncope, postural dizziness, neuropathic pain, tremor, abnormal gait
Very common (10% or more): Abnormal ECG (60%) including abnormal ECG in patients with a normal baseline (35%)
Common (1% to 10%): Tachycardia, arrhythmia, supraventricular tachycardia, flushing, hot flushes, hypertension, lymphedema, peripheral edema, chest pain
Uncommon (0.1% to 1%): Hypotension, peripheral coldness, orthostatic hypotension, chest discomfort, increased blood pressure
Rare (less than 0.1%): Bradycardia, cardiac arrest, left ventricular dysfunction, congestive heart failure, atrioventricular block, thrombosis
Very common (10% or more): Arthralgia/myalgia (44%)
Common (1% to 10%): Pain in extremity, bone pain, back pain, muscle cramps, limb pain, rigors
Uncommon (0.1% to 1%): Chest wall pain, muscular weakness, neck pain, groin pain, muscle spasms, musculoskeletal pain, flank pain, limb discomfort, muscle weakness
Very common (10% or more): AST (SGOT) elevations (39%), alkaline phosphatase elevations (36%), gamma-glutamyl transpeptidase (GGT) elevations (14%) patients
Common (1% to 10%): Bilirubin elevations
Uncommon (0.1% to 1%): Hepatomegaly
Rare (less than 0.1%): Hepatic necrosis, hepatic encephalopathy
Very common (10% or more): Nausea (30%), diarrhea (26%), vomiting (18%), constipation, stomatitis
Common (1% to 10%): Abdominal pain, abdominal distension, upper abdominal pain, dyspepsia, gastroesophageal reflux disease, oral hypoesthesia, mucosal inflammation
Uncommon (0.1% to 1%): Dysphagia, flatulence, glossodynia, dry mouth, gingival pain, esophagitis, lower abdominal pain, mouth ulceration, oral pain, rectal hemorrhage
Rare (less than 0.1%): Intestinal obstruction, intestinal perforation, pancreatitis, ischemic colitis, neutropenic enterocolitis
Very common (10% or more): Fatigue, asthenia, pyrexia
Common (1% to 10%): Vertigo, pain, edema, weakness, decreased performance status, malaise, lethargy, hyperpyrexia
Uncommon (0.1% to 1%): Ear pain, tinnitus
Common (1% to 10%): Upper respiratory tract infection, sinusitis, interstitial pneumonitis, dyspnea, epistaxis, pharyngolaryngeal pain, cough, rhinitis, rhinorrhea
Uncommon (0.1% to 1%): Nasopharyngitis, pneumonia, productive cough, exertional dyspnea, sinus congestion, decreased breath sounds, pleural effusion, allergic rhinitis, hoarseness, nasal congestion, nasal dryness, wheezing, pulmonary emboli, pulmonary thromboembolism
Very common (10% or more): Hypersensitivity (up to 12%)
Rare (less than 0.1%): Severe hypersensitivity
Uncommon (0.1% to 1%): Swelling, injection site reaction
Rare (0.01% to 0.1%): Extravasation
Common (1% to 10%): Increased lacrimation, blurred vision, dry eye, keratoconjunctivitis sicca, madarosis
Uncommon (0.1% to 1%): Eye irritation, eye pain, abnormal vision, reduced visual acuity, conjunctivitis, visual disturbance, eye pruritus, keratitis
Rare (less than 0.1%): Cystoid macular edema
Common (1% to 10%): Urinary tract infection
Uncommon (0.1% to 1%): Dysuria, pollakiuria, hematuria, nocturia, polyuria, urinary incontinence, breast pain
Very common (10% or more): Anorexia
Common (1% to 10%): Dehydration, hypokalemia, weight loss, increased alanine aminotransferase, increased aspartate aminotransferase, increased gamma-glutamyltransferase, decreased hematocrit, decreased red blood cell count, increased blood alkaline phosphatase
Uncommon (0.1% to 1%): Hypophosphatasemia, fluid retention, hypoalbuminemia, polydipsia, hyperglycemia, hypocalcemia, hypoglycemia, hyponatremia, weight gain, increased blood lactate dehydrogenase, increased blood creatinine, increased blood glucose, increased blood phosphorus, decreased blood potassium, increased bilirubin
Uncommon (0.1% to 1%): Metastatic pain, tumor necrosis
Common (1% to 10%): Insomnia, depression, anxiety
Uncommon (0.1% to 1%): Restlessness
Very common (10% or more): Infections (up to 24%)
Common (1% to 10%): Febrile neutropenia, folliculitis, candidiasis, influenza-like illness
Uncommon (0.1% to 1%): Neutropenic sepsis, oral candidiasis, cellulitis, herpes simplex, viral infection, catheter-related infection, fungal infection, herpes zoster, injection site infection, sepsis, neutropenic sepsis
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Paclitaxel (www.drugs.com/mtm/paclitaxel-protein-bound.html).
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
